Oncology

Cancer has a huge impact: It is estimated that in 2018, there were more than 18 million cancer diagnoses, and more than 9.5 million people died from cancer globally, with that number expected to increase. [1] This drives us to develop innovations that matter most to people living with cancer.

As these figures show, there is a continued need for patients to have access to new cancer treatments, particularly for those with hard-to-treat cancers. Our pioneering spirit drives us to help address this need by discovering and delivering innovative approaches to cancer care. We are harnessing this spirit and our strength as a global pharmaceutical company to invest significant resources into our research and development (R&D), which is demonstrated through our rapidly evolving pipeline of potential new cancer treatments.

But we know we cannot do this alone. It is our intent and endeavor to accelerate innovation in bringing new treatments to patients. To this end, we partner with some of the leading minds in the cancer community – from industry to academic institutions to leading cancer centers – to pursue integrated innovations that might have the potential to transform cancer care.

Yet innovation has to start on the front line, with patients and the people who take care of them. This is why we actively seek and listen to their feedback. We want to know what patients, caregivers and healthcare professionals need most. We then strive to transform their input into creative and innovative new approaches. 

Ultimately, we aspire to discover and develop diverse treatment options and new approaches to cancer care with the aim to make a meaningful difference to people living with cancer.